Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 35
- Registration Number
- NCT05926570
- Locations
- 🇪🇬
Sara Mabrouk Mohamed Elghoul, Tanta, Egypt
A Study of SHR6508 in Secondary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05663411
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Novel Combination Therapy for Osteoporosis in Men
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 40
- Registration Number
- NCT03994172
- Locations
- 🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 10
- Registration Number
- NCT03776058
Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT03774771
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
- Conditions
- Interventions
- First Posted Date
- 2017-10-03
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 637
- Registration Number
- NCT03299244
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT02525796
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Renal Osteodystrophy: An Individual Management Approach
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Hartmut Malluche, MD
- Target Recruit Count
- 141
- Registration Number
- NCT02440581
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Istituto Auxologico Italiano
- Target Recruit Count
- 22
- Registration Number
- NCT02417389
- Locations
- 🇮🇹
Istituto Auxologico Italiano IRCCS, Milano, Italy
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT02341417
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.